May 9, 2025
The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I The KETO-CTA Study
II Subclinical AF – Anticoagulate or Not?
Anticoagulation in Subclinical AF May Offer Little Benefit
https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31
Treat AFib ‘Diagnosed’ by Smartwatch
https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp
III GLP1a for Treatment of Fatty Liver Disease
Features
https://www.medscape.com/viewarticle/cabg-still-superior-stents-despite-fame-3-endpoint-swap-2025a1000ao5
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net